German biotech presents early cell therapy results for rare eye cancer at European conference
A German biotechnology company presented preliminary data from a study of sixteen patients with uveal melanoma at a major European oncology meeting last year.
Experimental treatment shows tumor reduction
Presenters displayed Phase 1 findings indicating that all participants experienced shrinking tumors after receiving the experimental cell therapy. The presentation took place during a prime time slot at the most significant European oncology conference held last year. Oncologist Sapna Patel explained these outcomes to an audience of thousands of global experts gathered in large rooms.
Potential impact on other cancer types
The data suggested that targeting this specific therapy could unlock immunotherapy power for other stubborn cancers like pancreatic and ovarian tumors. Patel told the conference that these results can be taken forward into other areas of oncology research. This approach might help treat conditions that have previously rebuffed such immunotherapy efforts.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.